Since Chinese officials slapped GlaxoSmithKline with a $489 million fine on bribery charges, the company has overhauled its sales practices to quash corruption there. But some in the industry say its reforms--which include eliminating sales-based compensation incentives for reps, nixing doctor speaking fees and tripling an in-house compliance team that checks every submitted receipt--could be negatively impacting its top line at a time when the company's already hurting.
Since Chinese officials slapped GlaxoSmithKline with a $489 million fine on bribery charges, the company has overhauled its sales practices to quash corruption. But some say its reforms could hurt its top line at a time when the company's already suffering.
A new study shows that prices for 19 brand-name dermatology meds, including two from Valeant Pharmaceuticals, have increased almost fivefold, on average, over the past 6 years.
GlaxoSmithKline's respiratory newcomers--and blockbuster hopefuls--Breo and Anoro got off to a slower start than analysts expected. That was a problem for the drugmaker, which was counting on them to make up for plummeting sales of Advair, as pricing pressure in the U.S. and generics in Europe took their toll on the behemoth med.
GlaxoSmithKline is taking a gamble on Idera Pharmaceuticals' antisense drug technology, promising up to $100 million in a collaboration focused on renal disease.
Médecins Sans Frontières, a global charity and frequent pharma critic, has initiated a worldwide petition calling for Pfizer and GlaxoSmithKline to reduce the prices of their pneumonia vaccines to $5 per child--for all three doses--in emerging markets and for humanitarian organizations.
GlaxoSmithKline's experimental Ebola jab, which was taken to Phase I in the U.S. and Mali last October, was well-tolerated and elicited strong immune responses in adults.
Bestselling asthma drugs from Novartis and respiratory behemoth GlaxoSmithKline are also showing more adverse events in post-marketing safety data than competing products from Merck, according to a new report, potentially presenting issues further down the line as companies duke it out for market share.
Throughout the tough times faced by the British biopharma industry, the country could always point to its scientific excellence as a source of pride. Now, with more money swilling around, the sector should be enjoying better days, yet as financial woes have receded another resource shortage has come into view: The United Kingdom appears to be running low on scientists.
GlaxoSmithKline has a vision for its respiratory unit that looks not unlike the portfolio approach some diabetes drugmakers have taken, with a range of therapies for different disease stages and different types of patients. And last week, the FDA approval of an add-on treatment for a subset of severe asthma patients brought it one step closer to achieving that vision.